These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
784 related articles for article (PubMed ID: 30718843)
1. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Camidge DR; Doebele RC; Kerr KM Nat Rev Clin Oncol; 2019 Jun; 16(6):341-355. PubMed ID: 30718843 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. Kim JH; Kim HS; Kim BJ Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386 [TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. Yang J; Chen J; Wei J; Liu X; Cho WC Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430 [TBL] [Abstract][Full Text] [Related]
4. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271 [TBL] [Abstract][Full Text] [Related]
5. [Application Progress of Immune Checkpoint Inhibitors in Oncogene-driven Advanced Non-small Cell Lung Cancer]. Zhang T; Li B Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):188-195. PubMed ID: 33819969 [TBL] [Abstract][Full Text] [Related]
6. [Research Progress on Predictive Biomarkers of Immunotherapy Efficacy in Non-small Cell Lung Cancer]. Sun T; Chen Z; Wei K; Tang H Zhongguo Fei Ai Za Zhi; 2024 Jun; 27(6):459-465. PubMed ID: 39026497 [TBL] [Abstract][Full Text] [Related]
7. When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer? Mhanna L; Guibert N; Milia J; Mazieres J Curr Treat Options Oncol; 2019 Jun; 20(7):60. PubMed ID: 31172347 [TBL] [Abstract][Full Text] [Related]
8. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Otano I; Ucero AC; Zugazagoitia J; Paz-Ares L Nat Rev Clin Oncol; 2023 Mar; 20(3):143-159. PubMed ID: 36639452 [TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). Yoneda K; Imanishi N; Ichiki Y; Tanaka F J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in patients who have NSCLC without EGFR or ALK mutations. Gandhi L Clin Adv Hematol Oncol; 2018 Jul; 16(7):484-485. PubMed ID: 30067619 [No Abstract] [Full Text] [Related]
11. [Cost Effectiveness and Health Economics of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer]. Kogure Y Gan To Kagaku Ryoho; 2018 May; 45(5):781-784. PubMed ID: 30026436 [TBL] [Abstract][Full Text] [Related]
12. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. Santana-Davila R; Chow LQ Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785 [No Abstract] [Full Text] [Related]
14. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. Monteiro ID; Califano R; Mountzios G; de Mello RA Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212 [TBL] [Abstract][Full Text] [Related]
17. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors? Rassy E; Mezquita L; Remon J; Besse B Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172 [TBL] [Abstract][Full Text] [Related]
18. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs? Attili I; Passaro A; Pavan A; Conte P; De Marinis F; Bonanno L Crit Rev Oncol Hematol; 2017 Nov; 119():30-39. PubMed ID: 29065983 [TBL] [Abstract][Full Text] [Related]
19. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions. Bhalla S; Doroshow DB; Hirsch FR Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722 [TBL] [Abstract][Full Text] [Related]
20. Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. Melosky B; Chu Q; Juergens RA; Leighl N; Ionescu D; Tsao MS; McLeod D; Hirsh V Cancer Treat Rev; 2018 Apr; 65():65-77. PubMed ID: 29567557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]